Analyst
Sales
Board Member
Xeris Biopharma Holdings, Inc. (XERS)Equibles does not estimate personal net worth.
Get an email with a short summary when Xeris Biopharma Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get XERS alertsJohn Shannon is recorded as Chairman at Xeris Biopharma Holdings, Inc. (XERS) since July 1, 2026, Board Member at Xeris Biopharma Holdings, Inc. (XERS) since August 1, 2024, COO and CEO at Xeris Biopharma Holdings, Inc. (XERS) and Analyst at Sales. The newest filing on record that lists John Shannon as CEO at Xeris Biopharma Holdings, Inc. (XERS) is dated April 23, 2026. Xeris Biopharma Holdings, Inc. reported in an 8-K filed June 30, 2026 that John Shannon was appointed Chairperson of the Board, effective July 1, 2026. Xeris Biopharma Holdings, Inc. reported in an 8-K filed July 8, 2024 that John Shannon was appointed Chief Executive Officer, effective August 1, 2024. Xeris Biopharma Holdings, Inc. reported in an 8-K filed July 8, 2024 that John Shannon was appointed Class III director, effective August 1, 2024. The proxy statement of Xeris Biopharma Holdings, Inc. reports total compensation of $5,042,584 for John Shannon in fiscal 2025, including a base salary of $742,334. Disclosed compensation is on record for 6 fiscal years. John Shannon has spoken on 8 earnings calls across 1 company, most recently for Xeris Biopharma Holdings, Inc. on March 2, 2026. Xeris Biopharma Holdings, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Xeris Biopharma Holdings, Inc. includes John P. Shannon (CEO and Board Member), Marla S. Persky (Chairman), Steven M. Pieper (CFO) and 7 others.
“On June 29, 2026, the Board appointed John Shannon, the Company’s Chief Executive Officer, to serve as Chairperson of the Board, effective as of July 1, 2026.”
“John Shannon, currently the Company's President and Chief Operating Officer, has been appointed by the Board to serve as the Company's Chief Executive Officer, effective as of the Transition Date.”
“We expected 2025 to be a transformational year for Xeris and it was. Our performance extended well beyond our incredible fourth quarter and full year revenue growth.”
“I'm excited to share that Q3 marked another record-setting quarter for Xeris. Total product revenue exceeded $74 million, representing a 40% increase year-over-year.”
“I'm excited to report that the strong momentum we established in the first quarter continued into the second quarter, driving another period of incredible performance and positioning us to outperform our original expectations for 2025.”
“I'm excited to announce that we're off to an exceptional start this year. In the first quarter, we delivered another record-breaking performance, growing total revenue by 48%.”
“2024 was an unprecedented year of exceptional commercial execution, focused pipeline development, and disciplined capital management.”
2026-07-01–present
2024-08-01–present
Sales
Analyst
Source not stated
Start not stated–present
Last confirmed April 23, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
COO, CEO, Chairman, Board Member
2024-08-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Xeris Biopharma Holdings, Inc. (XERS) | Chief Executive Officer | $742,334 | $5,042,584 |
| 2024 | Xeris Biopharma Holdings, Inc. (XERS) | Chief Executive Officer | $629,193 | $3,827,109 |
| 2023 | Xeris Biopharma Holdings, Inc. (XERS) | Chief Executive Officer | $571,411 | $1,848,153 |
| 2022 | Xeris Biopharma Holdings, Inc. (XERS) | Chief Executive Officer | $549,433 | $1,530,218 |
| 2021 | Xeris Biopharma Holdings, Inc. (XERS) | President and Chief Operating Officer | $527,500 | $1,728,640 |
| 2020 | Xeris Biopharma Holdings, Inc. (XERS) | President and Chief Operating Officer | $473,658 | $1,436,428 |
